ProKidney (NASDAQ:PROK) Trading Up 6.1%

Shares of ProKidney Corp. (NASDAQ:PROK - Get Free Report) traded up 6.1% during trading on Monday . The company traded as high as $2.37 and last traded at $2.25. 84,849 shares changed hands during trading, a decline of 88% from the average session volume of 687,234 shares. The stock had previously closed at $2.12.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Bank of America lowered ProKidney from a "buy" rating to a "neutral" rating in a research note on Tuesday, January 2nd. Morgan Stanley started coverage on ProKidney in a research note on Thursday, March 7th. They set an "equal weight" rating and a $3.00 price target on the stock.

ProKidney Price Performance

The company has a market capitalization of $527.48 million, a P/E ratio of -4.30 and a beta of 1.08. The stock has a 50-day moving average price of $1.73 and a 200-day moving average price of $1.69.

ProKidney (NASDAQ:PROK - Get Free Report) last issued its quarterly earnings data on Thursday, March 21st. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.19) by $0.10. Sell-side analysts anticipate that ProKidney Corp. will post -0.65 EPS for the current fiscal year.

Insider Transactions at ProKidney

In other ProKidney news, SVP Darin J. Weber sold 17,238 shares of ProKidney stock in a transaction that occurred on Tuesday, April 16th. The stock was sold at an average price of $2.50, for a total value of $43,095.00. Following the completion of the sale, the senior vice president now directly owns 172,432 shares in the company, valued at $431,080. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other ProKidney news, SVP Darin J. Weber sold 17,238 shares of ProKidney stock in a transaction that occurred on Tuesday, April 16th. The stock was sold at an average price of $2.50, for a total value of $43,095.00. Following the completion of the sale, the senior vice president now directly owns 172,432 shares in the company, valued at $431,080. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Darin J. Weber sold 16,438 shares of ProKidney stock in a transaction that occurred on Monday, April 22nd. The stock was sold at an average price of $2.51, for a total value of $41,259.38. Following the completion of the sale, the senior vice president now owns 155,194 shares of the company's stock, valued at $389,536.94. The disclosure for this sale can be found here. Insiders sold 118,879 shares of company stock worth $232,392 over the last ninety days. 44.99% of the stock is owned by insiders.

Institutional Investors Weigh In On ProKidney

A number of hedge funds have recently added to or reduced their stakes in PROK. Zullo Investment Group Inc. acquired a new stake in ProKidney in the first quarter valued at approximately $32,000. SG Americas Securities LLC acquired a new stake in ProKidney in the third quarter valued at approximately $78,000. Federated Hermes Inc. grew its stake in ProKidney by 10,984.7% in the fourth quarter. Federated Hermes Inc. now owns 113,286 shares of the company's stock valued at $202,000 after acquiring an additional 112,264 shares during the period. Finally, Jump Financial LLC acquired a new stake in ProKidney in the third quarter valued at approximately $216,000. 51.59% of the stock is currently owned by institutional investors.

ProKidney Company Profile

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.